Health & Medicine
-
Two Therapeutic Targets Identified for Deadly Lung Cancer
(July 26, 2019) The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results, published in the online version of Cancer Discovery on July 26, 2019, highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC.
Latest Research Articles
-
Finnish Company Uses NASA’s Concept to Create Food from Thin Air
-
ICR Claims New Gene Test Could Detect Prostate Cancer Patients
-
Microrobots Show Promise for Treating Tumors
-
Microfluidics Device Helps Diagnose Sepsis in Minutes
-
New Technique Could Help Engineer Polluted Water Filter, Human Tissues
-
Study: Fat Cells Play Key Role in Dangerous Transformation of Melanoma
-
UTSA Reduces Seizures by Removing Newborn Neurons
-
New Study Explains the Molecular Mechanism for the Therapeutic Effects of Cilantro
-
'Trojan Horse' Anticancer Drug Disguises Itself as Fat
-
OSHA Warns That Some Chemicals May Cause Hearing Loss
-
Novel Therapy Administered After TBI Prevents Brain Damage
-
Scientists Explore Blood Flow Bump that Happens When our Neurons are Significantly Activated